Literature DB >> 3802532

Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases.

A M Gressner, W Tittor, A Negwer, K H Pick-Kober.   

Abstract

In sera of patients with fibrotic liver diseases (n = 33) classified histologically into various degrees of liver fibrosis (n = 21) and cirrhosis (n = 12) the concentrations of the basement membrane protein laminin and of its pepsinresistant fragment P1 and of the N-terminal propeptide of type III procollagen were determined. The concentrations of both proteins were related to the portal venous pressure measured in these patients. Compared with the reference population (n = 146) the concentration of laminin increases from 1.04 U/ml (normal persons) to 1.69 +/- 0.46 U/ml in liver fibrotic and 2.58 +/- 0.87 U/ml in liver cirrhotic patients. Although the concentrations of the propeptide of type III procollagen increase also there exist only weak correlations between both connective tissue proteins in serum. Laminin is correlated highly positive with the portal venous pressure in cirrhotic subjects (r = 0.9206), the extent of laminin elevation reflects closely the degree of portal hypertension. Virtually all of the fibrotic patients having a laminin concentration within the reference range had a normal portal venous pressure. The data suggest laminin as a potentially useful parameter for monitoring the portal venous pressure in cirrhotic and severe fibrotic patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3802532     DOI: 10.1016/0009-8981(86)90008-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Liver fibrosis.

Authors:  A D Burt
Journal:  BMJ       Date:  1992-09-05

2.  Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma.

Authors:  Lu Liu; Zao Jiang; Gao-Jun Teng; Ji-Zhi Song; Dong-Sheng Zhang; Qing-Ming Guo; Wen Fang; Shi-Cheng He; Jin-He Guo
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

Review 3.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

Authors:  Moon Young Kim; Woo Kyoung Jeong; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Assessment of the fibrogenetic activity in chronic pancreatitis. The role of circulating levels of extracellular matrix components.

Authors:  J E Domínguez-Muñoz; G Manes; M Büchler; P Malfertheiner
Journal:  Int J Pancreatol       Date:  1993-12

5.  Uptake and degradation in vivo and in vitro of laminin and nidogen by rat liver cells.

Authors:  B Smedsrød; M Paulsson; S Johansson
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

6.  Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine.

Authors:  Qunying Han; Sai Lou; Zhengwen Liu; Ni Zhang; Guoyu Zhang; Yi Lv; Shaoqiong Duan; Zhu Li
Journal:  Clin Exp Med       Date:  2010-02-05       Impact factor: 3.984

7.  Serum concentrations of laminin in cirrhosis of the liver.

Authors:  J Collazos; F Díaz; J Genollá
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

8.  Noninvasive evaluation of portal hypertension: emerging tools and techniques.

Authors:  V K Snowdon; N Guha; J A Fallowfield
Journal:  Int J Hepatol       Date:  2012-06-07

Review 9.  Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality.

Authors:  O A Gressner; R Weiskirchen; A M Gressner
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

10.  Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.

Authors:  D J Leeming; M A Karsdal; I Byrjalsen; F Bendtsen; J Trebicka; M J Nielsen; C Christiansen; S Møller; A Krag
Journal:  Aliment Pharmacol Ther       Date:  2013-09-15       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.